Ambispective research about the association between adverse event and use of edaravone in patients with acute cerebral infarction.

Ambispective research about the association between adverse event and use of edaravone in patients with acute cerebral infarction. - Epidemiological research of Edaravone

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003938

Enrollment

6500

Registered

2010-07-24

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who visited hospital within 24 hours after clinical event and received acute care of cerebral infarction.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Renal disorder within 21 days.	—

Secondary

Measure	Time frame
Death within 30 days. And other adverse event, liver injury, thrombocytopenia and intracranial bleeding within 21 days	—

Countries

Japan

Contacts

Public ContactKunihiko Hayashi

Gunma University School of health science

khayashi@gunma-u.ac.jp027-220-8974

Outcome results